Lv21
170 积分 2025-09-14 加入
Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial
8小时前
已完结
Real-World Outcomes of Upadacitinib vs Risankizumab Among Anti-Tumor Necrosis Factor-Exposed Patients With Crohn's Disease
1个月前
已关闭
Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry
1个月前
已完结
Efficacy and Safety of Risankizumab in Crohn’s Disease: A Systematic Review and Meta-Analysis of Randomized Trials and Real-World Evidence
1个月前
已完结
Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study
1个月前
已完结
Mo1846: UPADACITINIB IS SAFE IN OLDER ADULTS: A RETROSPECTIVE REVIEW COMPARING SAFETY IN YOUNGER VS OLDER ADULTS
1个月前
已关闭
Stapokibart: First Approval
1个月前
已完结
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary
1个月前
已完结
Comparison of high‐dose dual therapy with bismuth‐containing quadruple therapy in Helicobacter pylori‐infected treatment‐naive patients: An open‐label, multicenter, randomized controlled trial
11个月前
已完结
皖公网安备34019202002308
